SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Status:
Recruiting
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, crossover study of SPI-62 in subjects with
ACTH-dependent Cushing's syndrome. Subjects will receive each of the following 2 treatments
for 12 weeks: SPI-62 and matching placebo